Episode Summary
In Episode 22 of Trucksafe LIVE!, host Brandon Wiseman speaks with Patrice Kelly, lead author of the U.S. Department of Transportation's final rule on oral fluid drug testing and the longest-serving director of the DOT's Office of Drug and Alcohol Policy and Compliance (ODAPC). The conversation centers on the final rule published in May 2023, which authorizes oral fluid testing as an alternative to urine testing for DOT-mandated drug tests. Wiseman and Kelly discuss what the rule means for regulated motor carriers, when implementation can realistically begin, and how the change fits into the broader landscape of transportation industry drug and alcohol compliance.
Kelly explains that oral fluid testing does not replace urine testing but gives employers a choice between the two methods. A key advantage of oral fluid testing is that every collection is inherently a directly observed collection, which significantly reduces opportunities for specimen adulteration or cheating. However, no laboratories have yet received HHS certification to process DOT oral fluid specimens, meaning carriers cannot begin using oral fluid testing to satisfy their DOT obligations immediately. Kelly advises fleet safety professionals to subscribe to the ODAPC listserv at www.transportation.gov/odapc and monitor communications from the National Drug and Alcohol Screening Association (NDASA) for updates on when certified laboratories become available.
The discussion covers several practical considerations for fleets, including the relevance of oral fluid testing for situations such as post-accident testing, where collecting a urine specimen in a remote location can be logistically difficult, and for employees with shy bladder conditions, where switching to oral fluid testing can save employers significant time and cost compared to the current multi-hour urine collection and MRO referral process. Kelly also notes that under the new rule, oral fluid testing will be required in circumstances involving transgender or non-binary employees when a same-gender collector cannot be identified, removing longstanding procedural uncertainty in those situations.
On the topic of detection windows, Kelly cautions that oral fluid testing generally detects drugs over a shorter window than urine, but emphasizes that chronic or regular drug users — including regular marijuana users — should not assume they can simply avoid use immediately before a test and pass. She also reiterates a strong warning about CBD products, noting that they are unregulated by the FDA, frequently contain THC, and continue to generate a significant number of marijuana positives among commercial drivers. Kelly stresses that a positive test result carries the same consequences regardless of the reason, and urges drivers to avoid CBD entirely until federal regulation of those products improves.
Wiseman closes the episode by highlighting the scale of the drug and alcohol problem in the industry — nearly 130,000 CDL drivers currently in prohibited status in the FMCSA Drug and Alcohol Clearinghouse — and touches on the White House's Recovery Ready Workplace initiative, which encourages employers to consider bringing employees back to safety-sensitive functions after successfully completing the return-to-duty process. Kelly notes that employers are not federally required to terminate employees following a positive test and that the costs of return-to-duty and follow-up testing can be passed back to the employee, creating additional accountability. Fleet safety professionals are encouraged to stay engaged with rulemaking processes, subscribe to ODAPC updates, and work with their drug and alcohol program service agents to prepare for oral fluid testing once laboratory certification is in place.